NEWS & MEDIA

Archive: 2021

JPEO-CBRND, JPM CBRN Medical Leads DOD Ebola Outbreak Response Efforts
April 28, 2021 — DISCLAIMER: Included references to commercial products does not constitute endorsement by the U.S. Department of Defense or the JPEO-CBRND. The year 2020 will undoubtedly be remembered as the year of the pandemic; the year the world was turned upside down by COVID-19. However, lurking in the shadows and out of the limelight, another viral outbreak...

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing
April 26, 2021 — In July 2020, Immunome was awarded a $13.3 million agreement from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program. The research discussed in this press release is part of that program...

JPM CBRN MEDICAL WINS BRONZE AT 2021 EDISON AWARDS
April 22, 2021 — RAIDR RF innovates and streamlines DOD medical acquisition...

SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial
April 21, 2021 — https://finance.yahoo.com/news/sab-biotherapeutics-doses-first-patient-200200245.html

SecondWave Systems secures over $7 Million from Department of Defense to Accelerate Development and Clinical Study of Novel Anti-Inflammatory Therapy based on Low-Intensity Focused Ultrasound Technology
April 20, 2021 — https://www.businesswire.com/news/home/20210420005207/en/SecondWave-Systems-secures-over-7-Million-from-Department-of-Defense-to-Accelerate-Development-and-Clinical-Study-of-Novel-Anti-Inflammatory-Therapy-based-on-Low-Intensity-Focused-Ultrasound-Technology

Microbiologics Expands Virology Services to Support Drug and Vaccine Researchers and Developers
April 14, 2021 — Increases capabilities and capacity to provide anti-infective testing, assay development and biomaterial production services for highly infectious pathogens...

JPEO-CBRND Investment Initiates Phase II Clinical Trial Using Tafenoquine to Treat COVID-19
March 12, 2021 — FOR IMMEDIATE RELEASE - The JPM CBRN Medical executed an agreement with 60P to study the effectiveness of an existing drug that shows promise against COVID-19.FORT DETRICK, Md. – February 22, 2021 – The Department of Defense (DOD) awarded a $5 million agreement to 60 Degrees Pharmaceuticals, LLC. (60P), to initiate a Phase II clinical trial to...

AstraZeneca to supply US with up to 500,000 additional doses of COVID-19 Long-Acting AntiBody combination AZD7442
March 12, 2021 — Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment...

Biden Administration secures supply of new COVID-19 therapeutic treatment
February 26, 2021 — FOR IMMEDIATE RELEASE - The Biden Administration announced today that it has secured a supply of a recently authorized COVID-19 therapeutic treatment. The U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) collaborated to purchase 100,000 treatment courses of a second therapeutic treatment from Eli Lilly and...

SARPAC Clinical Trial of Leukine® (sargramostim, rhu GM-CSF) in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function
February 26, 2021 — Link to full article - https://www.prnewswire.com/news-releases/sarpac-clinical-trial-of-leukine-sargramostim-rhu-gm-csf-in-hospitalized-covid-19-patients-meets-primary-endpoint-of-significant-improvement-in-lung-function-301236275.html

News Search

News Archive - Search by Year and Month

CPE CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the CPE CBRND's Capabilities Catalog, Leadership Biographies, and contracting overview documents.

CPE CBRND Public Affairs Office

The CPE CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the CPE CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.

The information contained in these articles has been reviewed and approved for public release.

The appearance of hyperlinks does not constitute endorsement by the CPE CBRND of non-U.S. government sites or the information, products, or services contained therein. Although the CPE CBRND may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all the information that you may find at these locations. Such hyperlinks are provided consistent with the stated purpose of this website.